Galenica Valuation
Is GALEZ undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
4/6Valuation Score 4/6
Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of GALEZ when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: GALEZ (CHF75.2) is trading below our estimate of fair value (CHF160.53)
Significantly Below Fair Value: GALEZ is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for GALEZ?
Other financial metrics that can be useful for relative valuation.
| What is GALEZ's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | CHF 3.75b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1.2x |
| Enterprise Value/EBITDA | 18.8x |
| PEG Ratio | 4.5x |
Price to Earnings Ratio vs Peers
How does GALEZ's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 31.8x | ||
MDC Mediclinic International | 21.9x | 10.7% | UK£3.7b |
CTEC ConvaTec Group | 41.1x | 21.0% | UK£4.7b |
SPI Spire Healthcare Group | 33.7x | 28.8% | UK£953.0m |
CVSG CVS Group | 30.4x | 18.8% | UK£797.7m |
GALEZ Galenica | 22.1x | 4.9% | CHF 3.7b |
Price-To-Earnings vs Peers: GALEZ is good value based on its Price-To-Earnings Ratio (22.1x) compared to the peer average (35.1x).
Price to Earnings Ratio vs Industry
How does GALEZ's PE Ratio compare vs other companies in the European Healthcare Industry?
Price-To-Earnings vs Industry: GALEZ is expensive based on its Price-To-Earnings Ratio (22.1x) compared to the European Healthcare industry average (19.1x).
Price to Earnings Ratio vs Fair Ratio
What is GALEZ's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 22.1x |
| Fair PE Ratio | 23.9x |
Price-To-Earnings vs Fair Ratio: GALEZ is good value based on its Price-To-Earnings Ratio (22.1x) compared to the estimated Fair Price-To-Earnings Ratio (23.9x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | CHF 75.20 | CHF 76.38 +1.6% | 8.2% | CHF 84.00 | CHF 68.00 | n/a | 4 |
| Sep ’25 | CHF 73.75 | CHF 76.88 +4.2% | 7.3% | CHF 84.00 | CHF 70.00 | n/a | 4 |
| Aug ’25 | CHF 76.70 | CHF 77.00 +0.4% | 7.4% | CHF 84.00 | CHF 70.00 | n/a | 4 |
| Jul ’25 | CHF 73.50 | CHF 77.00 +4.8% | 7.4% | CHF 84.00 | CHF 70.00 | n/a | 4 |
| Jun ’25 | CHF 74.50 | CHF 77.00 +3.4% | 7.4% | CHF 84.00 | CHF 70.00 | n/a | 4 |
| May ’25 | CHF 70.45 | CHF 76.25 +8.2% | 6.4% | CHF 81.00 | CHF 70.00 | n/a | 4 |
| Apr ’25 | CHF 75.15 | CHF 76.25 +1.5% | 6.4% | CHF 81.00 | CHF 70.00 | n/a | 4 |
| Mar ’25 | CHF 75.38 | CHF 76.25 +1.2% | 6.4% | CHF 81.00 | CHF 70.00 | n/a | 4 |
| Feb ’25 | CHF 75.85 | CHF 76.25 +0.5% | 6.4% | CHF 81.00 | CHF 70.00 | n/a | 4 |
| Jan ’25 | CHF 72.55 | CHF 75.25 +3.7% | 5.5% | CHF 81.00 | CHF 70.00 | n/a | 4 |
| Dec ’24 | CHF 72.20 | CHF 75.00 +3.9% | 5.1% | CHF 80.00 | CHF 70.00 | n/a | 4 |
| Nov ’24 | CHF 68.45 | CHF 74.50 +8.8% | 4.3% | CHF 78.00 | CHF 70.00 | n/a | 4 |
| Oct ’24 | CHF 67.75 | CHF 73.50 +8.5% | 5.0% | CHF 78.00 | CHF 68.00 | n/a | 4 |
| Sep ’24 | CHF 69.70 | CHF 73.40 +5.3% | 4.4% | CHF 78.00 | CHF 68.00 | CHF 73.75 | 5 |
| Aug ’24 | CHF 70.55 | CHF 72.40 +2.6% | 4.2% | CHF 76.00 | CHF 68.00 | CHF 76.70 | 5 |
| Jul ’24 | CHF 72.30 | CHF 72.40 +0.1% | 4.2% | CHF 76.00 | CHF 68.00 | CHF 73.50 | 5 |
| Jun ’24 | CHF 70.85 | CHF 73.75 +4.1% | 3.5% | CHF 77.00 | CHF 70.00 | CHF 74.50 | 4 |
| May ’24 | CHF 79.85 | CHF 70.50 -11.7% | 9.3% | CHF 77.00 | CHF 60.00 | CHF 70.45 | 4 |
| Apr ’24 | CHF 77.65 | CHF 69.50 -10.5% | 8.3% | CHF 75.00 | CHF 60.00 | CHF 75.15 | 4 |
| Mar ’24 | CHF 72.60 | CHF 68.75 -5.3% | 7.5% | CHF 73.00 | CHF 60.00 | CHF 75.38 | 4 |
| Feb ’24 | CHF 71.10 | CHF 68.75 -3.3% | 7.5% | CHF 73.00 | CHF 60.00 | CHF 75.85 | 4 |
| Jan ’24 | CHF 75.75 | CHF 68.75 -9.2% | 7.5% | CHF 73.00 | CHF 60.00 | CHF 72.55 | 4 |
| Dec ’23 | CHF 70.60 | CHF 68.50 -3.0% | 7.3% | CHF 72.00 | CHF 60.00 | CHF 72.20 | 4 |
| Nov ’23 | CHF 71.30 | CHF 68.50 -3.9% | 7.3% | CHF 72.00 | CHF 60.00 | CHF 68.45 | 4 |
| Oct ’23 | CHF 72.00 | CHF 68.50 -4.9% | 7.3% | CHF 72.00 | CHF 60.00 | CHF 67.75 | 4 |
| Sep ’23 | CHF 68.75 | CHF 68.50 -0.4% | 7.3% | CHF 72.00 | CHF 60.00 | CHF 69.70 | 4 |
Analyst Forecast: Target price is less than 20% higher than the current share price.